NCT06997952View on ClinicalTrials.gov

Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness

PHASE1CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 24, 2024

Primary Completion Date

August 24, 2024

Study Completion Date

August 24, 2024

Conditions

Carotid Intima- Media Thickness

Interventions

DRUG

Febuxostat 40 mg

Febuxostat will be given daily for 12 weeks The prescribed dosage was 40 mg taken once daily, self-administered by the patients in addition to their standard treatment.

Trial Locations (1)

11111

Ain Shams University, Cairo

All Listed Sponsors

lead

Ain Shams University

OTHER

NCT06997952 - Febuxostat Effect on Chronic Kidney Disease Progression And Carotid Intima-Media Thickness | Biotech Hunter | Biotech Hunter